0
INmune Bio Inc. Banner Image

INmune Bio Inc.

  • Ticker INMB
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
INmune Bio Inc. Logo Image
  • 1-10 Employees
  • Based in La Jolla, California
INmune Bio, Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms. The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and mechanistic target ofMore many diseases. DN-TNF is currently being developed for COVID-19 complications (Quellor™), cancer (INB03™), Alzheimer’s and treatment resistant depression (XPro595), and NASH (LIVNate™). The Natural Killer Cell Priming Platform includes INKmune™ aimed at priming the patient’s NK cells to eliminate minimal residual disease in patients with cancer. INmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation.
REPORT RATINGS
4.8 / 5.0 (186)

INmune Bio Inc. reports have an aggregate usefulness score of 4.8 based on 186 reviews.

INmune Bio Inc.

Most Recent Annual Report

INmune Bio Inc.
MOST RECENT 2022 Annual Report and Form 10K

Older/Archived Annual Reports

INmune Bio Inc. Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!